Pricing Log in Create free account
Friday 6 November 2026 Export DHR’s income statement to Excel — free account

Danaher Corporation

DHR Healthcare Diagnostics & Research

Danaher Corporation’s revenue for fiscal 2025 (year ended December 2025) was $24.6 billion, up 2.90% from fiscal 2024.

Revenue
+8.28%
EPS
+36.7%
Free cash flow
+19.1%
Total debt
+44.9%

Quarter to September 2026, against a year earlier

229.99 3.65 +1.61%
Market cap
$159.2B
P/E
37.0×
Fwd P/E
36.9×
Dividend yield
0.67%
F-score
6/9
Altman Z
4.52
Beneish M
−2.57
Dividend safety
69/100
Overview Business Profile Earnings & Analysis
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios
Segments Valuation Filings

Danaher Corporation 10-K filed Feb 24, 2026

Fiscal year 2025 · Period ended Dec 31, 2025 · Filed · accepted 4:36 PM ET · Document on sec.gov · Filing index

What changed

Item 1, Business Item 1A, Risk Factors Item 7, Management’s Discussion and Analysis

Item 1, Business, against the 10-K filed Feb 20, 2025: 2 added · 4 removed · 42 modified; 2 with only figures updated

  1. Modified · General

    Danaher is a global science and technology innovator committed to accelerating the power of science and technology to improve human health. Danaher is comprised of more than 15 operating companies with leadership positions in the biotechnology, life sciences and diagnostics sectors, organized under three segments (Biotechnology, Life Sciences and Diagnostics). United by the DANAHER BUSINESS SYSTEM (“DBS”), our businesses are also typically characterized by a high level of products and services that are sold on a recurring basis, primarily through a direct sales model and to a geographically diverse customer base. Our business’ research and development, manufacturing, sales, distribution, service and administrative facilities are located in more thanapproximately 50 countries.